Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, China.
College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China.
Biomed Pharmacother. 2020 Dec;132:110765. doi: 10.1016/j.biopha.2020.110765. Epub 2020 Oct 28.
Hyperuricemia (HUA) is a metabolic disease caused by the overproduction or underexcretion of uric acid (UA). Our previous study found that treatment with Dendrobium officinalis six nostrum (DOS) led to a significant reduction in serum UA (SUA) by inhibiting UA production and promoting UA excretion in a rat model of HUA induced by potassium oxonate (PO) and high-fat sorghum feed. In this study, we aimed to further investigate the effects of DOS on UA excretion by the kidney and intestine to explore whether DOS protects against histopathological changes, and to elucidate its possible mechanisms of action in a lipid emulsion (LE)-induced rat model of HUA.
The main chemical constituents of DOS were determined to be acteoside and astilbin by high-performance liquid chromatography (HPLC). Three different doses of DOS (3.3, 6.6, and 13.2 g/kg/day) were given to rats daily after induction of HUA by oral administration of LE for 8 weeks. The levels of creatinine (Cr) in serum and urine and UA in serum, urine, and feces were measured by an automatic biochemical analyzer. The expression of TLR4, NF-κB and urate transport-related transporters (URAT1, ABCG2, and PDZK1) in kidney was measured by Western blot (WB). Intestinal urate transporters (ABCG2 and GLUT9) expression was assayed by IHC and WB. Serum LPS and renal inflammatory factors (IL-6, IL-8 and TNF-α) levels were measured using enzyme-linked immunosorbent assay (ELISA) kits. Hematoxylin and eosin (H&E) staining was used to assess renal histological changes.
DOS treatment significantly reduced the SUA and SCr levels by increasing urine volume, 24 h urine uric acid (UUA), fecal UA (FUA), urine creatinine (UCr), and fractional excretion of UA (FEUA) levels in hyperuricemic rats. Moreover, DOS effectively regulated URAT1, PDZK1, and ABCG2 protein levels in the kidney, as well as restored protein levels of GLUT9 and ABCG2 in the intestine. DOS markedly reduced serum LPS anddown-regulated renal TLR4 and NF-κB protein levels to suppress IL-6, IL-8, and TNF-α secretion. It also improved renal inflammation in hyperuricemic rats. In addition, DOS attenuated histopathological changes in the kidneys of LE-induced rats. HPLC analysis showed levels of acteoside and astilbin of 1.39 mg/g and 0.72 mg/g in DOS, respectively.
DOS has anti-hyperuricemic and anti-inflammatory effects in a rat model of HUA. The molecular mechanism appears to involve the regulation of urate transport-related transporters including renal ABCG2, URAT1, and PDZK1, and intestinal GLUT9 and ABCG2, as well as the inhibition of the LPS/TLR4/NF-κB signaling to reduce IL-6, IL-8, and TNF-α secretion in hyperuricemic rats.
高尿酸血症(HUA)是一种由于尿酸(UA)产生过多或排泄减少而导致的代谢性疾病。我们之前的研究发现,铁皮石斛六株制剂(DOS)可通过抑制尿酸产生和促进尿酸排泄,显著降低氧嗪酸钾(PO)和高脂高粱饲料诱导的 HUA 大鼠模型的血清 UA(SUA)。在本研究中,我们旨在进一步研究 DOS 对肾脏和肠道 UA 排泄的影响,以探讨 DOS 是否能预防组织病理学变化,并阐明其在脂乳(LE)诱导的 HUA 大鼠模型中的可能作用机制。
采用高效液相色谱法(HPLC)测定 DOS 的主要化学成分是紫云英苷和毛蕊花糖苷。在通过口服 LE 诱导 HUA 8 周后,每天给予大鼠 3.3、6.6 和 13.2 g/kg/day 三种不同剂量的 DOS。采用自动生化分析仪检测血清和尿液中的肌酐(Cr)和 UA 水平,以及血清、尿液和粪便中的 UA 水平。采用 Western blot(WB)检测 TLR4、NF-κB 和尿酸转运相关转运体(URAT1、ABCG2 和 PDZK1)在肾脏中的表达。采用免疫组织化学(IHC)和 WB 检测肠道尿酸转运体(ABCG2 和 GLUT9)的表达。采用酶联免疫吸附试验(ELISA)试剂盒检测血清脂多糖(LPS)和肾脏炎症因子(IL-6、IL-8 和 TNF-α)水平。采用苏木精和伊红(H&E)染色评估肾脏组织学变化。
DOS 治疗可通过增加尿量、24 小时尿液 UA(UUA)、粪便 UA(FUA)、尿液 Cr 和 UA 排泄分数(FEUA)水平,显著降低 HUA 大鼠的 SUA 和 SCr 水平。此外,DOS 还可有效调节肾脏中 URAT1、PDZK1 和 ABCG2 蛋白水平,并恢复肠道中 GLUT9 和 ABCG2 的蛋白水平。DOS 还可显著降低血清 LPS 水平,并下调肾脏 TLR4 和 NF-κB 蛋白水平,从而抑制 IL-6、IL-8 和 TNF-α的分泌,改善 HUA 大鼠的肾脏炎症。此外,DOS 可减轻 LE 诱导的大鼠肾脏的组织病理学变化。HPLC 分析显示,DOS 中紫云英苷和毛蕊花糖苷的含量分别为 1.39mg/g 和 0.72mg/g。
DOS 对 HUA 大鼠具有抗高尿酸血症和抗炎作用。其分子机制可能涉及调节尿酸转运相关转运体,包括肾脏 ABCG2、URAT1 和 PDZK1,以及肠道 GLUT9 和 ABCG2,并抑制 LPS/TLR4/NF-κB 信号通路,减少 HUA 大鼠中 IL-6、IL-8 和 TNF-α的分泌。